Y-mAbs Therapeutics

YMAB

Börsenwert 391 Mio. $

After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pick from a technical perspective. YMAB recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB) to SERB Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Y-mAbs will receive $8.60 in cash for each share of Y-mAbs that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Y-mAbs will receive $ $8.60 per share in cash, representing approx.

Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The company beat expectations on both revenue and earnings per share, posting GAAP revenue of $19.5 million against a GAAP consensus of $18.4 million, and GAAP EPS of ($0.07) compared to an analyst estimate of ($0.26).

PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025.

NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) related to its sale to SERB Pharmaceuticals.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB) to SERB Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Y-mAbs will receive $8.60 in cash for each share of Y-mAbs that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025.

YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.